GSK's Trelegy Ellipta Gains New Indication in the US for the Treatment of Patients...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Apr 25, 2018 at 9:52 AM.

  1. #1 cafead, Apr 25, 2018 at 9:52 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,028
    Likes Received:
    3
    via GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced on 4/24/18 that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means Trelegy Ellipta can now be used by US physicians to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who have experienced an acute worsening of respiratory symptoms.

    article source
     
    Quote

Reply to Thread